← Leaderboards
Song Gao
University Of Houston
$4,835,728
Attributed
$4,835,728
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,835,728 · 6
By mechanism
U54$3,751,171 · 3
R15$472,250 · 1
R16$460,140 · 1
R03$152,167 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationAwardToxic EffectCareerDrug MetabolismMolecularEnvironmentDrug CandidateTrainingStructureUnderrepresented MinorityDrug DevelopmentAnimalsPublishingInstitutionPreventUnited States National Institutes Of HealthAffectFormulationAnimal ModelBiological AvailabilityFacultyFundingArea
Grant awards (11)
Research Capacity Core$1,017,215
U54 · FY2025 · MD · contact PI
Selectively Manipulating Intestinal Glucuronidation to Alleviate Mycophenolate mofetil-induced Diarrhea$153,380
R16 · FY2025 · GM · contact PI
Research Infrastructure Core$942,530
U54 · FY2024 · MD · contact PI
Selectively Manipulating Intestinal Glucuronidation to Alleviate Mycophenolate mofetil-induced Diarrhea$153,380
R16 · FY2024 · GM · contact PI
Selectively Manipulating Intestinal Glucuronidation to Alleviate Mycophenolate mofetil-induced Diarrhea$153,380
R16 · FY2023 · GM · contact PI
Research Infrastructure Core$588,199
U54 · FY2022 · MD · contact PI
Research Infrastructure Core$604,628
U54 · FY2021 · MD · contact PI
Research Infrastructure Core$598,599
U54 · FY2020 · MD · contact PI
Developing Locally Bioavailable Drugs to Inhibit the Aberrantly Elevated PEG2 in the Colon$472,250
R15 · FY2018 · GM · contact PI
Developing Recycled Colon Bioavailable (r-CB) COXIBs for the Treatment of Familial adenomatous polyposis (FAP)$76,500
R03 · FY2018 · CA · contact PI
Developing Recycled Colon Bioavailable (r-CB) COXIBs for the Treatment of Familial adenomatous polyposis (FAP)$75,667
R03 · FY2017 · CA · contact PI